

ALYSSA M. VANDERBEEK

New York, NY

(508) 505-8260 | amv2187@cumc.columbia.edu

[Website](#) | [GitHub](#) (alyssamv) | [LinkedIn](#) (alyssavanderbeek)

August 2019

EDUCATION

Columbia University, New York, NY
M.S. Biostatistics – GPA 3.75

May 2020 (Expected)

Wheaton College, Norton, MA
B.A. Mathematics

May 2016

AWARDS & HONORS

Hispanic Scholarship Fund Scholar – Fall 2018

RESEARCH EXPERIENCE

Data Science Institute Scholar, Columbia University, New York, NY

June 2019 – Present

Principal Investigators: Maxim Topaz, RN, PhD

- Help develop software in R to process clinical notes using combined natural language processing (NLP) and machine learning

Assistant Statistician, Columbia University, New York, NY

May 2019 – Present

Principal Investigators: Steven Shea, MD & Seamus (JLP) Thompson, PhD

- Manage data and perform analysis on data for ROKHYT pilot study, examining preliminary effectiveness of text messaging interventions to improve hypertension

Research Assistant, Columbia University, New York, NY

Sept 2018 – Present

Supervising Faculty: Codruta Chiuzan, PhD

- Build [R package](#) to simulate and implement early-phase two-stage adaptive dose-finding design, developed by [Chiuzan et al.](#)
- Developing extension of design to alternative endpoints

Research Assistant, [Dana-Farber Cancer Institute](#), Boston, MA

Oct 2016 – July 2018

Principal Investigator: Brian M. Alexander, MD, MPH

- Identify data sources; clean and maintain datasets; perform analysis and simulations in R
- Develop informatics tools to acquire and handle data from online sources
- Assist in development on biostatistical methods pertaining to clinical trial design/conduct

PUBLICATIONS

* Authors contributed equally

1. **Vanderbeek AM**, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy T, Wen P, Trippa L, Alexander BM. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? *Neuro-Oncology*. April 2018.
2. Rahman R, Ventz S, Fell G, **Vanderbeek AM**, Trippa L, Alexander BM. Divining Responder Populations from Survival Data. *Annals of Oncology*. March 2019.
3. **Vanderbeek AM***, Ventz S*, Rahman R, Fell G, Trippa L, Alexander BM. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. *Accepted manuscript; Neuro-Oncology*, May 2019.
4. Rahman R, Fell G, Ventz S, Arfe A, **Vanderbeek AM**, Trippa L, Alexander BM. Deviation from the proportional hazards assumption in randomized phase 3 oncology clinical trials: prevalence, associations, and implications. *Clinical Cancer Research*. July 2019.

CONFERENCES

Posters

- “To randomize or not to randomize”. 3rd Annual Stat4Onc. May 2019.

Presentations

- (Accepted abstract) “iAdapt – an R package and Shiny app for simulation and implementation of early phase dose-finding designs incorporating toxicity and continuous efficacy outcomes”. 2020 ASA Conference on Statistical Practice. February 2020.

OTHER RELEVANT EXPERIENCE

Information Analyst, Definitive Healthcare, Natick, MA Aug 2016 – Oct 2016

- Web application development and maintenance (use of SQL Server, HTML)
- Relational database management using SQL Server (5 databases)
- Create custom data reports for clients

Student, Summer Institute for Training in Biostatistics, Boston University, Boston, MA Summer 2015

- Competitive six-week full-time intensive introduction to biostatistics
- Training in SAS and using data from the Framingham Heart Study

SKILLS

Computer: R, SQL, LaTeX, Python (pandas), SAS, HTML5, Stata, PASS

Language: English (native), French (intermediate)